Y Maezawa1, G Paltser1, H Tsui1, R Cheung1, P Wu1, A P Nicholas2,3, H-M Dosch1. 1. The Hospital for Sick Children Research Institute, Neuroscience and Mental Health, University of Toronto, Toronto, ON, Canada. 2. Department of Neurology and Center for Neuroimmunology, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Birmingham VA Medical Center, Birmingham, AL, USA.
Abstract
BACKGROUND: Citrullination is a presently under-recognized posttranslational protein modification catalyzed by PAD enzymes. Immune responses to citrullinated neo-epitopes are identified in a growing number of inflammatory and autoimmune diseases. However, the involvement of hypercitrullination in the pathogenesis of bronchial asthma is still unknown. METHODS: As main experimental tool, we examined the effect of 2-chloroacetamidine (2CA), a PAD enzyme inhibitor, on OVA-immunized and airway-challenged BALB/c mice; a commonly used model of allergic airway inflammation. We also measured the effect of 2CA on ex vivo lymphocytes and cell lines. RESULTS: In vivo, 2CA dramatically suppressed lung tissue hypercitrullination, inflammatory cell recruitment, and airway-Th2 cytokine secretion. 2CA also suppressed systemic OVA-specific and total IgE production dramatically, effectively preventing de novo and diminishing established disease without measurably impacting general immunocompetence. In vitro, 2CA markedly inhibited the proliferation of mouse and human T cells with cell cycle block and apoptosis during a limited, postactivation phase. CONCLUSIONS: 2CA acts as narrow-spectrum immunosuppressant that selectively targets lymphocyte populations involved in active inflammatory tissue lesions. If hypercitrullination is generated in patients with asthma, 2CA may represent a novel disease modulator for human asthmatics/allergic diseases.
BACKGROUND: Citrullination is a presently under-recognized posttranslational protein modification catalyzed by PAD enzymes. Immune responses to citrullinated neo-epitopes are identified in a growing number of inflammatory and autoimmune diseases. However, the involvement of hypercitrullination in the pathogenesis of bronchial asthma is still unknown. METHODS: As main experimental tool, we examined the effect of 2-chloroacetamidine (2CA), a PAD enzyme inhibitor, on OVA-immunized and airway-challenged BALB/c mice; a commonly used model of allergic airway inflammation. We also measured the effect of 2CA on ex vivo lymphocytes and cell lines. RESULTS: In vivo, 2CA dramatically suppressed lung tissue hypercitrullination, inflammatory cell recruitment, and airway-Th2 cytokine secretion. 2CA also suppressed systemic OVA-specific and total IgE production dramatically, effectively preventing de novo and diminishing established disease without measurably impacting general immunocompetence. In vitro, 2CA markedly inhibited the proliferation of mouse and human T cells with cell cycle block and apoptosis during a limited, postactivation phase. CONCLUSIONS: 2CA acts as narrow-spectrum immunosuppressant that selectively targets lymphocyte populations involved in active inflammatory tissue lesions. If hypercitrullination is generated in patients with asthma, 2CA may represent a novel disease modulator for human asthmatics/allergic diseases.
Authors: Bo Sun; Hui-Hsin Chang; Ari Salinger; Beverly Tomita; Mandar Bawadekar; Caitlyn L Holmes; Miriam A Shelef; Eranthie Weerapana; Paul R Thompson; I-Cheng Ho Journal: JCI Insight Date: 2019-11-14
Authors: Víctor Casanova; Filipa Henderson Sousa; Priyanka Shakamuri; Pavel Svoboda; Chloé Buch; Mathilde D'Acremont; Maria A Christophorou; Jan Pohl; Craig Stevens; Peter G Barlow Journal: Front Immunol Date: 2020-02-04 Impact factor: 7.561
Authors: Willie Elliott; Maheedhara R Guda; Swapna Asuthkar; Narasaraju Teluguakula; Durbaka V R Prasad; Andrew J Tsung; Kiran K Velpula Journal: Biomedicines Date: 2021-12-09